Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas

Wouter Froyman; Chiara Landolfo; Frédéric Amant; Thierry Van den Bosch; Ignace Vergote; An Coosemans; Antonia Testa; Lil Valentin; Tom Bourne; Ben Van Calster; Dirk Timmerman

doi:10.1016/S1470-2045(16)00022-X

Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas

Wouter Froyman, Chiara Landolfo, Frédéric Amant, Thierry Van den Bosch, Ignace Vergote, An Coosemans, Antonia Testa, Lil Valentin, Tom Bourne, Ben Van Calster, Dirk Timmerman

Obstetrisk, gynekologisk och prenatal ultraljudsdiagnostik

Forskningsoutput: Tidskriftsbidrag › Debate/Note/Editorial › Peer review

Originalspråk	engelska
Sidor (från-till)	273-4
Antal sidor	2
Tidskrift	The Lancet Oncology
Volym	17
Nummer	3
DOI	https://doi.org/10.1016/S1470-2045(16)00022-X
Status	Published - 2016 mars

Ämnesklassifikation (UKÄ)

Cancer och onkologi
Reproduktionsmedicin och gynekologi

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1016/S1470-2045(16)00022-X

Citera det här

@article{7e224478988149d7a9072208f0ab2aaa,

title = "Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas",

author = "Wouter Froyman and Chiara Landolfo and Fr{\'e}d{\'e}ric Amant and {Van den Bosch}, Thierry and Ignace Vergote and An Coosemans and Antonia Testa and Lil Valentin and Tom Bourne and Calster, {Ben Van} and Dirk Timmerman",

year = "2016",

month = mar,

doi = "10.1016/S1470-2045(16)00022-X",

language = "English",

volume = "17",

pages = "273--4",

journal = "The Lancet Oncology",

issn = "1474-5488",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas

AU - Froyman, Wouter

AU - Landolfo, Chiara

AU - Amant, Frédéric

AU - Van den Bosch, Thierry

AU - Vergote, Ignace

AU - Coosemans, An

AU - Testa, Antonia

AU - Valentin, Lil

AU - Bourne, Tom

AU - Calster, Ben Van

AU - Timmerman, Dirk

PY - 2016/3

Y1 - 2016/3

U2 - 10.1016/S1470-2045(16)00022-X

DO - 10.1016/S1470-2045(16)00022-X

M3 - Debate/Note/Editorial

C2 - 26972853

SN - 1474-5488

VL - 17

SP - 273

EP - 274

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -